Furthermore, the combination therapy of Ad-ΔB/IL-12 with Ad-ΔB/TRAIL exhibits an enhanced anti-tumor immune response due to IL-12 being able to upregulate the TRAIL expression of NK cells, resulting in IFN-γ-dependent NK cell-related tumor metastasis inhibition (45, 100). The gene discussed is IFNG; the disease is neoplasm.